[SCHEDULE 13G/A] Innate Pharma SA Amended Passive Investment Disclosure

SCHEDULE 13G

CUSIP Number(s):

45781K105

1

Names of Reporting Persons

Novo Nordisk A/S

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,718,727.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,718,727.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,718,727.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.03 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Innate Pharma SA

(b)

Address of issuer's principal executive offices:

117 Avenue de Luminy, BP 30191, Marseille, France, 13009

Item 2.

(a)

Name of person filing:

Novo Nordisk A/S

(b)

Address or principal business office or, if none, residence:

Novo Alle 1, DK-2880, Bagsvaerd Denmark

(c)

Citizenship:

Denmark

(d)

Title of class of securities:

Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

4,718,727

(b)

Percent of class:

5.03%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

4,718,727

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

4,718,727

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Nordisk A/S

Signature:	/s/ Karsten Munk Knudsen
Name/Title:	Karsten Munk Knudsen, Chief Financial Officer
Date:	04/10/2026

[SCHEDULE 13G/A] Innate Pharma SA Amended Passive Investment Disclosure

Rhea-AI Filing Summary

Positive

Negative